1. PD-L1 as a Companion Biomarker for Immune Checkpoint Inhibitors in NSCLC: Should RNA ISH (RISH) Be Considered? 
Steven G. Gray, PhD 
Journal of Thoracic Oncology 
Volume 11, Issue 11, Pages e142-e144 (November 2016)
DOI: /j.jtho
Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

2. Figure 1
Kaplan-Meier plot analysis of 1926 patients with NSCLC for CD274 (PD-L1) demonstrating that high expression of PD-L1 messenger RNA is associated with better overall survival. HR, hazard ratio.
Journal of Thoracic Oncology  , e142-e144DOI: ( /j.jtho )
Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions